About Us:
MSM Protein technologies is an antibody drug discovery with "best in class" expertise at the generation of fully human antibodies targeted to GPCRs and other complex cell surface receptors. MSM has successfully completed more than a dozen projects aimed at generating functional human antibodies to GPCRs, both in collaborations with corporate partners and for its own internal pipeline.
The company is based in Medford, MA and has an affiliate company, Meprotek, in Puschino, Russia. Both companies are fully configured to conduct the full spectrum of antibody drug discovery activities from target selection through to the delivery of an optimized human antibody.
MSM was founded in 2005 based upon target display technology developed by one of the founders at Harvard Medical School. Since that time the company has expanded its technology platform with a number of new methods that strengthen our ability to select antibodies with greater sensitivity and specificity.
MSM has collaborated with some of the leading companies in the industry including Astra-Zeneca, Merck-Serono and DebioPharm. We are actively seeking new partners for de novo discovery efforts as well as to help us advance our existing pipeline of anti-GPCR antibodies for cancer, auto-immune diseases, inflammation and metabolic disorders.
